| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers S > Headlines for Sunesis Pharmaceuticals, Inc. > News item |
Sunesis starts phase 1 trial of SNS-595 for acute leukemia
New York, Nov. 15 - Sunesis Pharmaceuticals, Inc. said it has begun treatment of patients with refractory acute leukemias in a phase 1 clinical trial of its lead small molecule drug, SNS-595.
The study is an open-label, multi-center, dose-escalation assessment of the safety, tolerability and pharmacokinetics of SNS-595. Sunesis aims to establish an optimal dosing regimen for use in planned phase 2 clinical testing of patients with relapsed or refractory acute myelocytic leukemia and potentially other acute leukemias.
"The commencement of this phase I trial for SNS-595 allows us to explore the potential benefits of SNS-595 in patients with acute leukemias. Based on the strong myelosuppressive effects of SNS-595 seen at higher doses in our phase I clinical trials in patients with advanced solid malignancies, we believe SNS-595 has the potential to offer a significant advance in the treatment of acute leukemias," said Daniel Adelman, senior vice president of research and development at Sunesis, quoted in a news release.
The South San Francisco, Calif., biopharmaceutical company will enroll patients at three centers in the United States, the H. Lee Moffitt Cancer Center & Research Institute, MD Anderson Cancer Center and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University.
Patients will receive SNS-595 either as three weekly doses per treatment cycle or twice weekly for four doses per treatment cycle.
SNS-595 acts during the S phase of the cell cycle to induce rapid apoptosis of cells that are actively synthesizing DNA. In clinical trials conducted to date, SNS-595 has been well tolerated and has shown promising signs of clinical activity, Sunesis said. The drug has exhibited broad activity in xenograft studies and drug-resistant tumor models.
SNS-595 is being evaluated in phase 1 clinical studies and will be soon entering phase 2 clinical trials in lung cancer.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.